Skip to main content
SpringerLink
Log in

Growth factors and hematopoietic recovery

  • Review Article
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Availability of hematopoietic growth factors (GC-SF, GM-CSF, erythropoietin,etc.) has started a new arena of dose-intensification. The use of such growth factors has resulted in faster hematopoietic recovery of cancer patients and now offers several new treatment modifications. These include: (1)dose-intensification without hematopoietic stem cell support, (2) speedier hematopoetic recovery after hematoablative therapy and stem cell transplantation (allogeneic or autologous); (3) use of combination of growth factors, and (4) improvement in the delivery of anti-microbial drugs which are toxic towards hematopoietic cells (Gancyclovir, Bactrim,etc.). The above treatment strategies are under active clinical trials and can provide improved, cost-effective methods of treating patients with cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lieschke G J and Burgess A W. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor.N Eng J Med,327,28–35 (1992).

    CAS  Google Scholar 

  2. Lieschke G J and Burgess A W. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor.N Eng J Med,327,99–106 (1992).

    CAS  Google Scholar 

  3. DeWitte T, Gratwohl A, Van Der Lely N, Bacigalupo A, Stern A C, Speck B, Schattenberg A, Nissen C, Gluckrnan E and Fibbe W E. Recombinant human granulocyte-macrophage colony-stimulating factor accelerates neutrophil and monocyte recovery after allogeneic Tcelldepleted bone marrow transplantation.Blood,79,1359–1365 (1992).

    CAS  Google Scholar 

  4. Fritsch G, Emminger W, Buchinger P, Printz D and Gadner H. CD34+ cell proportions in peripheral blood correlate with colonyforming capacity.Exp Hematol,19,1079–1083 (1991).

    PubMed  CAS  Google Scholar 

  5. Siena S, Bregni M, Brando B, Belli N, Ravagnani F, Gandola L, Stern A C, Landsdorp P M, Bonadonna G and Ganni A M. Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients.Blood,77,400–409 (1991).

    PubMed  CAS  Google Scholar 

  6. Janssen W E, Farmelo M J, Lee C, Smilee R, Kronish L and Elfenbein G J. The CD34+ cell fraction in bone marrow and blood is not universally predictive of CFUGM.Exp Hematol 20,528–530 (1992).

    PubMed  CAS  Google Scholar 

  7. Siena S, Bregni M, Gianni A M and Janssen W E. Estimation of peripheral blood CD34+ cells for autologous transplantation in cancer patients:Exp Hematol,21,203–205 (1993).

    PubMed  CAS  Google Scholar 

  8. Jones R J, Sharkis S J, Celano P, Colvin O M, Rowley S C and Sensenbrenner L L. Progenitor cell assays predict hematopoietic reconstitution after syngeneic transplantation in mice.Blood,70,1186–1192 (1987).

    PubMed  CAS  Google Scholar 

  9. Gulati S C.Purging in bone marrow transplantation. R.G. Landes, CRC Press, 2000 Corporate Boulevard, Boca Raton, FL 33431 (1993).

    Google Scholar 

  10. Douay L, Gorin N C, Mary J Y, Lemarie E, Lopez M, Najman A, Stachowiak J, Giarratana M C, Bailou C, Salmon C and Duhamel G. Recovery of CFUGM from cryo-preserved bone marrow andin vivo evaluation after autologous bone marrow transplantation are predictive of engraftment.Exp Hematol,14,358–365 (1986).

    PubMed  CAS  Google Scholar 

  11. Atkinson K, Biggs J C, Downs K, Juttner C, Bradstock K, Lowenthal R M, Dale B, Szer J. GMCSF after allogeneic bone marrow transplantation: accelerated recovery of neutrophils, monocytes and Iymphocytes.Aust NZ J Med 21,686–692 (1991).

    CAS  Google Scholar 

  12. Nemunaitis J, Rabinowe S N, Singer J W, Bierman P J, Vose J M, Freedman A S, Onetto N, Giltis S, Oette D, Gold M, Buckner D, Hansen J A, Ritz J, Appelbaum F R, Armitage J O, Nadler L M. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for Iymphoid cancer.N Eng J Med,324,1773–1778 (1991).

    CAS  Google Scholar 

  13. Gianni A M, Bregni M, Stern A C, Siena S, Tarella C, Pileri A and Bonadonna G. granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation.Lancet, 580–585 (1989).

  14. Gulati S C and Bennett C L. granulocyte-macrophage colony-stimulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin Disease.Annals of lnternal Medicine,116,177–182 (1992).

    CAS  Google Scholar 

  15. Bot F J, van Eijk L, Schipper P, Backx B and Lowenberg B. Synergistic effects between GMC-SF and GC-SF or MC-SF on highly enriched human marrow progenitor cells.Leukemia,4,325–328 (1990).

    PubMed  CAS  Google Scholar 

  16. Morstyn G, Campbell L, Lieschke G, Layton J E, Maher D, O’Connor M, Green M, Sheridan W, Vincent M, Alton K, Souza L, McGrath K, Fox R M. Treatment of chemotherapy-induced neutropenia by subcutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy.J Clin Oncol,7,1554–1562 (1989).

    PubMed  CAS  Google Scholar 

  17. Bender J G, Bik To L, Williams S, Schwartzberg L S. Defining a therapeutic dose of peripheral blood stem cells.J Hematotherapy,1,329–341 (1992).

    CAS  Google Scholar 

  18. To L B, Haylock D N, Dyson P G, Thorp D, Roberts M M, Juttner C A. An unusual patter of hematopoietic reconstitution in patients with acute myeloid leukemia transplanted with autologous recovery phase peripheral blood.Bone Marrow Transplant,5,109–114 (1990).

    Google Scholar 

  19. Harrison D E, Jordan C T, Zhong R K and Astle C M. Primitive hemopoietic stem cells: direct assay of most productive populations by competitive repopulation with simple binomial, correlation and covariance calculations.Exp Hematol,21,206–219 (1993).

    PubMed  CAS  Google Scholar 

  20. Lopez M, Mary J Y, Sainteny F.Invitro purging of bone marrow with mafosfamide synergizes withinvivo chemotherapy to delay the hematological recovery in a murine model of autologous bone marrow transplantation.Exp Hematol,21,311–318 (1993).

    PubMed  CAS  Google Scholar 

  21. Brenner M K, Rill D, Moen R C,et al. Genemarking to trace origin of relapse after autologous bone marrow transplantation.Lancet,341,85–86 (1993).

    Article  PubMed  CAS  Google Scholar 

  22. MacKintosh F R, Adlish J, Hall S W, St.Joer S, Smith E, Tavassoli M and Zanjani E D. Suppression of normal human hematopoiesis by cytomegalovirusinvitro.Exp Hematol,21,243–250 (1993).

    PubMed  CAS  Google Scholar 

  23. Schwartzberg L S, Birch R, Hazelton B, Tauer K W, Lee P Jr, Altemose R, George C, Blanco R, Wittlin F, Cohen J, Muscato J and West W H. Peripheral blood stem cell mobilization by chemotherapy with or without recombinant human granulocyte colony-stimulating factor.J Hematotherapy,1,317–327 (1992).

    CAS  Google Scholar 

  24. Moore M A S. Does stem cell exhaustion result from combining hematopoeitic growth factors with chemotherapy? If so, how do we prevent it?Blood,80,3–7 (1992).

    PubMed  CAS  Google Scholar 

  25. Bitran J, White L, Okuno T, Martinec J, Samuels B and Klein L. Mobilization of early hematopoietic progenitors after high dose cyclophosphamide alone and cyclophosphamide and thiotepa.ASCO,12,1527 (1993).

    Google Scholar 

  26. Fleischlauer K, Kernan N, O’Reilly R J, Dupont B and Young Yang S. Bone marrowallograft rejection by Tlymphocytes recognizing a single amino acid difference in HLAB44.N Engl J Med,323,1381–1822 (1990).

    Google Scholar 

  27. Emerson S G, Sieff C A, Gross R G, Rozans M K, Miller R A, Rappeport J M and Nathan D G. Decreased hematopoietic accessory cell function following bone marrow transplantation.Exp Hematol,15,1013–1021 (1987).

    PubMed  CAS  Google Scholar 

  28. Straus S E, Cohen J, Tosato G and Meier J. Epstein Barr virus infections: Biology, pathogenesis, and management.Annals of Internal Medicine,118,45–58 (1993).

    PubMed  CAS  Google Scholar 

  29. Anderson L J and Torok T. Human Parvovirus B19.NEJM,321,536–538 (1989).

    PubMed  CAS  Google Scholar 

  30. Matthews J H. Pulmonary toxicity of ABVD chemotherapy and GCSF in Hodgkin’s disease: Possible synergy.Lancet,342,988 (1993).

    Article  PubMed  CAS  Google Scholar 

  31. Iki S, Yoshinaga K, Ohbayashi Y,et al. Cytotoxic drug-induced pneumonia and possible augmentation b GCSFClinical attention.Ann Hematol 66,217–218 1993.

    Article  PubMed  CAS  Google Scholar 

  32. Brugger W, Bross K, Fisch J,et al. Mobilization of peripheral blood progenitor cells by sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following polychemotherapy with etoposide, if osfamide, and cisplatin.Blood,79,1193–1200 (1992).

    PubMed  CAS  Google Scholar 

  33. Neidhart J, Mangalik A, Stidley C, Tebich S, Sarmiento L, Pfile J, Oette D and Oldhan F. Dosing regimen of granulocyte-macrophage colony-stimulating factor to support dose-intensive chemotherapy.J Clin Oncol,10,1460–1469 (1992).

    PubMed  CAS  Google Scholar 

  34. Wing E J, Magee D M, Whiteside T L, Kaplan S S and Shadduck R K. Recombinant human granulocyte-macrophage colony-stimulating factor enhances monocyte cytotoxicity and secretion of tumor necrosis factor a and interferon in cancer patients.Blood,73,643–646 (1989).

    PubMed  CAS  Google Scholar 

  35. Rabinowitz J, Petros W P, Stuart A R and Peters W P. Characterization of endogenous cytokine concentrations alter highdose chemotherapy with autologous bone marrow support.Blood,81,2452–2459 (1993).

    PubMed  CAS  Google Scholar 

  36. Kawano Y, Takaue Y, Saito S I, Sato J, Shimuzu T, Suzue T, Hirao A, Okamoto Y, Abe T, Watanabe T, Kuroda Y, Kimura F, Motoyoshi K and Asano S. Granulocyte colony-stimulating factor macrophage CSF, granulocyte-macrophage CSF, interleukin-3, and interleukin-6 levels in sera from children undergoing blood stem cell autografts.Blood,81,856–860 (1993).

    PubMed  CAS  Google Scholar 

  37. Locatelli F, Pedrazzoli P, Barosi G, Zecca M, Porta F, Liberato L, Gambarana D, Nespoli L and Cassola M. Recombinant human erythropoietin is effective in correcting erythropoietin-deficient anemia after allogeneic bone marrow transplantation.British J Haematol,80,545–549 (1992).

    Article  CAS  Google Scholar 

  38. Miller C B, Platanias L C, Mills S R, Zahurak M L, Ratain M J, Ettinger D S and Jones R J. Phase 111 trial of erythropoietin in the treatment of cisplatinassociated anemia.J Natl Cancer Inst,84,98–103 (1992).

    Article  PubMed  CAS  Google Scholar 

  39. Platanias L C, Miller C B, Mick R, Hart R D, Ozer H, McEvilly J M, Jones R J and Ratain M J. Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients.J Clin Oncol,9,2021–2026 (1991).

    PubMed  CAS  Google Scholar 

  40. Gulati S C, Bennett C, Phillips J and Van Poznak C. GMCSF as an adjunct to autologous bone marrow transplantation.Stem Cells,11,20–25 (1993).

    Article  PubMed  CAS  Google Scholar 

  41. Crown J, Kritz A, Vahdat L, Reich L, Moore M, Hamilton N, Schneider J, Harrison M, Gilewski T, Hudis C, Gulati S C and Norton L. Rapid administration of multiple cycles of highdose myelosuppressive chemotherapy in patients with metastatic breast cancer.JCO,11,1144–1149 (1993).

    CAS  Google Scholar 

  42. Rubinstein P, Rosenfield R E, Adamson J W and Stevens C E. Stored placental blood for unrelated bone marrow reconstitution.Blood,81,1679–1690 (1993).

    PubMed  CAS  Google Scholar 

  43. Brugger W, Klaus J B Glattet al. Mobilization of tumor cells and hematopoietic progenitor cell into peripheral blood of patients with solid tumors.Blood,83,636–640 (1994)

    PubMed  CAS  Google Scholar 

  44. Gulati S C. Did we focus on the most important issues in the use of growth factors and stem cell transplantation?J Clin Oncol,12,650–652 (1994).

    PubMed  CAS  Google Scholar 

  45. Kutsogiannis D J, Crowther M A and Lazarovitis A I, Granulocyte-macrophage colony-stimulating factor for the therapy of cytomegalovirus and gancyclovir-induced leukopenia in a renal transplant recipient.Transplantation,53,930–932 (1992).

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology Oncology, Cornell University Medical College, 1300 York Avenue, 10021, New York, NY

    Subhash C. Gulati, Ravi Gopal, Judith B. Prowda, Stanislov Spanik, Maneesh Jain & Ajay Gopal

Authors
  1. Subhash C. Gulati
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ravi Gopal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Judith B. Prowda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stanislov Spanik
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Maneesh Jain
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ajay Gopal
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gulati, S.C., Gopal, R., Prowda, J.B. et al. Growth factors and hematopoietic recovery. Med Oncol 11, 1–6 (1994). https://doi.org/10.1007/BF02990084

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02990084

Key Words

Search

Navigation